MA
Therapeutic Areas
Precision BioSciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| PBGENE-HBV | Chronic Hepatitis B Virus (HBV) Infection | Phase 1/2 |
| PBGENE-DMD | Duchenne Muscular Dystrophy (DMD) | Phase 1/2 |
| PBGENE-PMM | Primary Mitochondrial Myopathy (PMM) | Preclinical |
| Azer-cel | B-cell Malignancies / Autoimmune Diseases | Phase 1/2 |
| ECUR-506 | Ornithine Transcarbamylase (OTC) Deficiency | Phase 1/2 |
Leadership Team at Precision BioSciences
JA
John A. Kelly, Ph.D.
Chief Scientific Officer & SVP, Research
JT
John T. Crowley
Chief Financial Officer & SVP, Corporate Development
BD
B. Derek Smith, Ph.D.
Chief Operating Officer
BD
Brendan D. Hannah, Ph.D.
SVP, General Counsel & Corporate Secretary
NT
Naresh Tanna
Vice President of Investor Relations